The peptide weight loss landscape divides cleanly into two categories: FDA-approved drugs with extensive human clinical trial data, and research-grade compounds where the evidence base is thinner but the interest is real. Understanding which category a compound falls into matters before making any protocol decisions.
This article distinguishes carefully between FDA-approved compounds with Phase 3 clinical trial data and research-grade compounds where evidence is primarily preclinical or early-stage. This distinction matters significantly for both efficacy expectations and safety assessment.
Tier 1: FDA-approved — strongest clinical evidence
1. Tirzepatide (Mounjaro / Zepbound) — the current standard
The SURMOUNT-5 trial confirmed tirzepatide produces approximately 20.2% average body weight reduction over 72 weeks — more than any other FDA-approved weight loss medication. Its dual GIP/GLP-1 mechanism drives appetite suppression, improved insulin sensitivity, and enhanced fat mobilisation simultaneously.
SURMOUNT-1 trial: −20.9% body weight at 72 weeks (15mg dose). SURMOUNT-5 head-to-head vs semaglutide: tirzepatide superior at all doses. FDA-approved for type 2 diabetes (Mounjaro) and obesity (Zepbound).
The practical constraint is cost and access. LillyDirect self-pay vials at $299–$499/month represent the most accessible cash-pay route as of 2026, following the end of most compounded tirzepatide availability.
2. Semaglutide (Wegovy / Ozempic) — the proven standard
Semaglutide produces approximately 15% average body weight reduction in the STEP trials and carries additional evidence for cardiovascular risk reduction via the SELECT trial. Its longer track record and more established prescribing infrastructure make it the default starting point for many providers.
For patients where the 6.5 percentage point weight loss difference between tirzepatide and semaglutide is meaningful, tirzepatide is the better choice. For patients already responding well to semaglutide, the case for switching is less compelling.
Tier 2: FDA-approved for related indications — strong evidence, off-label weight use
3. Tesamorelin (Egrifta) — visceral fat specialist
FDA-approved for HIV-associated lipodystrophy, tesamorelin is a GHRH analogue that produces approximately 18% reduction in visceral adipose tissue in clinical trials. Unlike GLP-1 drugs which produce general body weight reduction, tesamorelin specifically targets metabolically active visceral fat — the fat most strongly associated with cardiovascular risk.
It also has uniquely strong cognitive data — a randomised controlled trial showed significant improvement in executive function and memory in mild cognitive impairment. This makes it a compound of particular interest in longevity-oriented protocols where both body composition and cognitive preservation are goals.
Tier 3: Research-grade with human trial data — moderate evidence
4. MK-677 (Ibutamoren) — oral GH secretagogue
The only oral growth hormone secretagogue with a 2-year randomised controlled trial. MK-677 raises GH and IGF-1 to levels comparable to younger adults — producing improvements in lean body mass and bone density. Its weight loss effect is indirect: by preserving and building lean mass while supporting fat metabolism, it improves body composition rather than reducing scale weight directly.
The primary trade-off is significant appetite stimulation from its ghrelin-mimicking mechanism. Users without disciplined dietary management can gain fat alongside lean mass. Not a weight loss compound in the GLP-1 sense — but a meaningful body composition tool.
5. Retatrutide — the next frontier (Phase 3 pending)
The triple GLP-1/GIP/glucagon agonist from Eli Lilly showed 24.2% average weight loss in Phase 2 trials — the highest ever recorded for a pharmacological intervention at the time. Phase 3 results are expected 2025–2026 and will determine whether these results translate to a larger, more diverse population.
Research-grade retatrutide is available but carries significant sourcing quality concerns — the synthesis is complex and most market product is of uncertain quality. Not recommended over tirzepatide or semaglutide unless Phase 3 data confirms the Phase 2 results and proper sourcing channels are established.
What actually works — an honest framework
The evidence hierarchy for weight loss peptides is stark. GLP-1 receptor agonists — tirzepatide and semaglutide — are in a different league from everything else. They produce 15–20%+ weight loss in large Phase 3 trials. No other peptide class comes close to this magnitude of effect in human data.
Growth hormone axis peptides (tesamorelin, MK-677, ipamorelin/CJC-1295) produce meaningful body composition changes but modest weight loss. They are best understood as lean mass preservation and visceral fat tools — valuable in conjunction with GLP-1 drugs or for users focused on body composition rather than scale weight.
The community frequently discusses GH secretagogue stacks (ipamorelin + CJC-1295) for fat loss. These can produce real improvements in body composition over 12–16 week cycles, but the magnitude is substantially smaller than GLP-1 drugs and the evidence base is thinner. They serve a different population — those wanting optimisation without the significant appetite suppression of GLP-1s.
The muscle loss problem — applicable to all weight loss peptides
Any protocol producing significant weight loss risks lean mass loss alongside fat loss. This is particularly relevant for GLP-1 users where rapid weight reduction can include substantial muscle loss without intervention.
The practical solution applies regardless of which compound you're using: minimum 1.6g protein per kilogram of body weight daily, resistance training at least 3 times per week, and consider GH axis support (ipamorelin, tesamorelin, or MK-677) to preserve lean mass during a GLP-1 protocol.